Integrated Drug Discovery: why expertise matters
See how chemistry, biology, DMPK, and DMTA expertise with a trusted preclinical CRO make integrated drug discovery faster and more reliable. Read now.
A step-by-step guide for conducting safe and successful bile duct cannulated PK studies
In recent years, the biopharmaceutical industry has increasingly focused on reducing animal testing when conducting safety and efficacy studies for new drugs. Ethical considerations, regulatory guidelines, and advancements in alternative testing methods like artificial intelligence have driven this shift.
Bispecific antibodies: engineering complexity into simplicity
Clear guidance on bispecific antibodies, from formats and engineering to analytics and control strategy, for scalable development and manufacturing. Read now.
Integrated Expertise for Complex Modalities: Driving Innovation in Molecular Glue Discovery
Prove induced proximity in molecular glues with ITC, fluorescence polarization, and co-IP. Practical steps for stronger discovery decisions. Read the guide.
Translational and Clinical Research services
Syngene’s data consortium comprises a group of consenting clients working towards greater learning through predictive modeling to enable faster drug discovery.
GLP-certified viral testing and clearance services
Syngene offers GLP-certified viral testing and clearance services with flexible scheduling and rapid turnaround, supporting over 100 global clinical programs. Their facility is India’s only GLP-certified site for viral safety studies, ensuring compliance with FDA, EMA, and WHO regulations. Services include viral clearance studies, cell bank testing, and in-process/batch testing for biologics.
Transforming Cell Line Development with Syngene’s SynWeave™ Platform
Built on a proprietary CHO cell line and transposon-based technology, SynWeave™ enables the rapid generation of high-yield, stable, and homogeneous clones. The platform integrates advanced clone screening using the Ambr-250 bioreactor, allowing for comprehensive evaluation of titer, key product quality attributes, and process parameters, accelerating your path to robust cell line development.
Syngene’s new biologics facility in the U.S.
Our expanded biologics manufacturing facility in Bayview, Maryland marks a strategic step forward in meeting the growing needs of our global customers. The addition of this facility increases Syngene’s total single-use bioreactor capacity to 50,000 liters, featuring 2,000 and 4,000 liters bioreactors designed to deliver economies of scale.
Your one-stop-shop for XDCs
Syngene offers an integrated bioconjugation platform for XDCs, providing end-to-end support from antibody discovery to GMP manufacturing at up to 1 kg scale. Their expertise covers diverse conjugation technologies, payload and linker chemistry, and advanced analytical and bioassay support. Syngene ensures single-source manufacturing of antibodies, peptides, oligonucleotides, payloads, and linkers, minimizing risk and delays.
Plasmid, mRNA, & Viral Vector Manufacturing: Scaling for the Gene Therapy Boom
Explore how plasmid DNA, mRNA CDMO, and viral vector manufacturing are scaling to meet the rising demand of AAV gene therapy and genetic medicines. Read on to know more.